Lamassu
ACCELERATING HOPE AND HEALING

10000 Cedar Avenue
Cleveland, OH 44106
(919) 667-8571
www.LamassuBiotech.com



ACCELERATING HOPE AND HEALING

Accelerating treatment, means saving more lives. At Lamassu, our team of dedicated physicians, engineers, and translational scientists are driven by a passion to treat patients like family. Our goal is to speed the innovation process by bringing transformational treatments from concept to bedside faster than other companies. Lamassu's patient-centric approach to research focuses on making advancements that address unmet needs with novel and targeted strategies, ensuring greater efficiency and shorter approval timeframes. With decades of experience developing leading medical treatments, we believe that it is not only the transformative power of science, but also hope that leads to healing.

THE LAMASSU METHOD

While the process of proving new drugs to be a safe and effective treatment is a vital one, the need to accomplish this more quickly is also clear, particularly for patients waiting for life saving treatments. Lamassu combines innovative scientific approaches with collaboration between academia and industry through translational research. Our model is to identify novel therapeutics with high potential for clinical impact, having strong scientific rationale and preclinical efficacy data. We build the best scientific case, examining the mechanism, exploring additional models and indications, and identifying the most promising path forward for regulatory approval and clinical impact. **We capitalize on our expertise in early translational research to bring products to Phase I/II and partner with clinical and commercial development specialists to advance clinical trials through the approval pipeline.** Our innovative model ensures that early development efforts bring products to definitive clinical testing as efficiently as possible to benefit patients, while safeguarding safety and investments.

HIGH LEVEL STRATEGY

- ✓ Rare Disease
- ✓ Accelerate Approval
- ✓ Academic Center/NIH Partnership
- ✓ Best in Class Assets
- ✓ Potential Voucher
- ✓ Patient Recruitment

OUR PARTNERS

NIH National Cancer Institute · cqdm · Mayo Clinic · NIH National Institutes of Health · Université de Montréal · SAYDI BIOTECH · Cleveland Clinic · ARRIVO BIOVENTURES · McGill University


Gabi Hanna, MD
Chief Executive Officer


Greg Palmer, PhD
Chief Science Officer


Rabi Hanna, MD
Chief Medical Officer

Lamassu
ACCELERATING HOPE AND HEALING



PIPELINE

Our product pipeline is earning recognition from top regulatory agencies and leading to strong partnerships that can move these transformative approaches from the lab to the bedside. Lamassu's momentum has been the result of years of analysis and collaboration to address some of the most pressing health concerns faced by patients the world over. At Lamassu, we're accelerating hope and healing.

SA53 MDM2

P53 is a crucial tumor suppressor gene commonly mutated in human cancers. Its role in preventing tumor formation by inducing programmed cell death in response to cellular stress makes it a key target for cancer therapy. The project focuses on advancing SA53, a novel therapeutic that targets p53 wild-type sarcomas, malignant tumors of connective or non-epithelial tissue.

SA53 has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission. This innovative approach offers promising prospects for addressing chemo-resistant cancer and presents a significant pathway for advancing cancer care.

The proposed therapy aims to trigger the body's natural defense mechanism, p53 by blocking MDM2, a protein that deactivates p53 and contributes to treatment resistance. The clinical trial will focus on achieving objectives such as determining a safe dosage for future trials, understanding pharmacokinetic profiles, and assessing early signs of effectiveness in treating soft tissue sarcomas with wild-type p53. The main goal is to advance SA53 through trials to offer a potential new and effective treatment option for patients.

SA53 MDM2 is currently undergoing Phase 1 trial in partnership with the Cleveland Clinic.

Cleveland Clinic

LATEST DEVELOPMENTS

NIH NATIONAL CANCER INSTITUTE

Awarded $2.05 Million Grant

In 2023, Lamassu was awarded a grant from the National Institutes of Health (NIH) and National Cancer Institute (NCI) for the development of their groundbreaking treatment for p53 wild-type sarcomas. The $2.05 million grant will help fund the clinical trial integral to this new cancer treatment. The trial will be conducted in collaboration with Cleveland Clinic Taussig Cancer Center and Cleveland Clinic Children's Pediatric Hematology and Oncology Department.

FDA

IND Approval to initial Phase 1/2A Clinical Trials

Lamassu Biotech's pioneering effort to combat locally advanced metastatic p53 wild-type tumors using novel therapy SA53-OS, a genetically targeted therapy that targets the MDM2 protein, a key regulator of the tumor suppressor p53 gene.

RABI-767

Acute pancreatitis is one of the most common causes of inpatient hospital care in the United States, with an incidence of 57-60 cases and mortality of 1.12 per 100,000 person per year. RABI-767 is a molecule therapy for acute pancreatitis, developed at the Mayo Clinic. RABI-767 has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis.

Recently successfully completed a Phase 1 Human Healthy Volunteer Clinical Trial.

ARRIVO BIOVENTURES

Lamassu is currently focused on continued development of this compound through safety testing in preparation for definitive clinical trials with the ultimate goal of saving the lives of patients afflicted with this disease. During the last 4 years Lamassu Pharma and its partners, Arrivo BioVentures and the Mayo Clinic, with support of a funded NIH SBIR phase II grant (awarded in 2020), have successfully completed all toxicology, IND enabling studies in dogs and rats, small molecule synthesis development, scale up and GMP manufacturing, and recently successfully completed a Phase 1 human healthy volunteer clinical trial. Lamassu is currently seeking funds through NIH SBIR IIB to optimize and accelerate the development and translation of the treatment.

INTERESTED IN COLLABORATING OR PARTNERING WITH LAMASSU?

Contact:

Dr. Gabi Hanna, Chief Executive Officer
gabi.hanna@lamassupharma.com

+1.919.667.8571
www.LamassuBiotech.com

Lamassu
ACCELERATING HOPE AND HEALING